
Supreme Court declines relief to Zydus Lifesciences in breast cancer drug case
Zydus had approached the Supreme Court challenging the Delhi High Court’s order, which prevented the company from producing and marketing breast cancer drug Sigrima.

Zydus had approached the Supreme Court challenging the Delhi High Court’s order, which prevented the company from producing and marketing breast cancer drug Sigrima.

The IT index has tumbled over 1,300 points today and has corrected more than 2,600 points from its record high level of 43,645.90, which it…

Apart from banking and financial services, Rajeev Agrawal, Managing Partner and Fund Manager at DoorDarshi India Fund finds good opportunities emerging in the capital market…

Wood said that under a Democrat-leadership, the semiconductor technology policy would have been a status-quo, which would have meant further deterioration of the US-China relationship.

According to Bloomberg data, since November 5, stocks in South Korea have plunged as much as 8%, followed by Hong Kong (5.4%), France (5.1%), Switzerland…

With government spending and primary sales improving, we should actually have a good second half of the year, says Mihir Vora, Chief Investment Officer (CIO)…

Brokerage firm Jefferies maintained its “buy” recommendation on the stock with a price target of ₹2,200, which is higher than the recent highs made by…

Surya Roshni Share Price | The stock opened at ₹590 apiece on the BSE on Monday, marking a 3.55% decline from the previous close of…

Despite a 32% correction from its July peak so far, brokerage firm Nirmal Bang sees limited upside in shares of Mazagon Dock.

Crompton Greaves Share Price | In a stock exchange filing, the company said that its consolidated profit after tax (PAT) witnessed a 27% at ₹128…